Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Investments (2020 - 2025)

Amphastar Pharmaceuticals has reported Long-Term Investments over the past 6 years, most recently at $14.5 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $14.5 million for Q4 2025, up 31.87% from a year ago — trailing twelve months through Dec 2025 was $14.5 million (up 31.87% YoY), and the annual figure for FY2025 was $14.5 million, up 31.87%.
  • Long-Term Investments for Q4 2025 was $14.5 million at Amphastar Pharmaceuticals, up from $13.3 million in the prior quarter.
  • Over the last five years, Long-Term Investments for AMPH hit a ceiling of $14.5 million in Q4 2025 and a floor of $527000.0 in Q4 2023.
  • Median Long-Term Investments over the past 5 years was $4.7 million (2022), compared with a mean of $6.2 million.
  • Biggest five-year swings in Long-Term Investments: tumbled 88.29% in 2023 and later surged 1986.53% in 2024.
  • Amphastar Pharmaceuticals' Long-Term Investments stood at $3.4 million in 2021, then skyrocketed by 32.35% to $4.5 million in 2022, then tumbled by 88.29% to $527000.0 in 2023, then surged by 1986.53% to $11.0 million in 2024, then soared by 31.87% to $14.5 million in 2025.
  • The last three reported values for Long-Term Investments were $14.5 million (Q4 2025), $13.3 million (Q3 2025), and $12.1 million (Q2 2025) per Business Quant data.